Transdermal patches: history, development and pharmacology
Tóm tắt
Transdermal patches are now widely used as cosmetic, topical and transdermal delivery systems. These patches represent a key outcome from the growth in skin science, technology and expertise developed through trial and error, clinical observation and evidence‐based studies that date back to the first existing human records. This review begins with the earliest topical therapies and traces topical delivery to the present‐day transdermal patches, describing along the way the initial trials, devices and drug delivery systems that underpin current transdermal patches and their actives. This is followed by consideration of the evolution in the various patch designs and their limitations as well as requirements for actives to be used for transdermal delivery. The properties of and issues associated with the use of currently marketed products, such as variability, safety and regulatory aspects, are then described. The review concludes by examining future prospects for transdermal patches and drug delivery systems, such as the combination of active delivery systems with patches, minimally invasive microneedle patches and cutaneous solutions, including metered‐dose systems.
Từ khóa
Tài liệu tham khảo
Acrux Ltd(2014).Data estimated from the ‘US testosterone therapy market histogram’. Annual Report 2014 [Online]. Available at:http://www.acrux.com.au/IRM/Company/ShowPage.aspx/PDFs/1381‐10000000/2014AnnualReport(accessed 10/28/2014).
Aiache JM, 1984, Historique des emplâtres, Bull Tech Gattefossé, 77, 9
BakerRW KochinkeF(1989).Novel transdermal nicotine patch. US Patent 4 839 174 Pharmetrix Corporation.
BannonYB CorishJ CorriganOI GeogheganEJ MastersonJG(1994).Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method. US Patent 5 298 257 Elan Transdermal Limited.
Barrett DA, 1994, Transdermal delivery and the premature neonate, Crit Rev Ther Drug Carrier Syst, 11, 1
Bender GA, 1966, Great Moments in Medicine and Pharmacy: a History of Medicine and Pharmacy in Pictures
Benowitz NL, 1982, Interindividual variability in the metabolism and cardiovascular effects of nicotine in man, J Pharmacol Exp Ther, 221, 368
Berner B, 1987, Transdermal Delivery of Drugs, 41
Brown EW, 1934, The absorption of methyl salicylate by the human skin, J Pharmacol Exp Ther, 50, 32
Bryan CP, 1930, The Papyrus Ebers
CampbellPS ChandrasekaranSK(1983).Dosage for coadministering drug and percutaneous absorption enhancer. US Patent 4 379 454 Alza Corporation.
CampbellPS ChandrasekaranSK(1984).Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer. US Patent 4 460 372 Alza Corporation.
CampbellPS EckenhoffJB(1987).Transdermal therapeutic system having improved delivery characteristics. US Patent 4 704 282 Alza Corporation.
CampbellPS EckenhoffJB PlaceVA(1988).Transdermal drug delivery device. US Patent 4 725 439 Alza Corporation.
CampbellPS EckenhoffJB PlaceVA(1989a).Transdermal drug delivery device. US Patent 4 867 982 Alza Corporation.
CampbellPS EnscoreDJ GaleR KaufmanA(1989b).Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix. US Patent 4 832 953 Alza Corporation.
Caplan RA, 1989, Transdermal fentanyl for postoperative pain management. A double‐blind placebo study, JAMA, 261, 1036, 10.1001/jama.1989.03420070086036
Castle T, 1828, Lexicon Pharmaceuticum: Or a Pharmaceutical Dictionary, Comprehending the Pharmacopoeias of London, Edinburgh, and Dublin, with a Variety of Other Use
Chambers Fox S, 2014, Remington Education: Pharmaceutics
ChandrasekaranSK DardaS MichaelsAS ClearyGW(1980).Therapeutic system for administering clonidine transdermally. US Patent 4 201 211 Alza Corporation & Boehringer Ingelheim GmbH.
ChiangC‐C LinT‐S ChenR(2009).Compositions and methods for the transdermal delivery of pharmaceutical compounds. US Patent Application 2009/0297591 A1 Orient Pharma Co. Ltd.
ClearyGW RoySD(1993).Laminated composite for transdermal administration of fentanyl. US Patent 5 186 939 Cygnus Therapeutic Systems.
Coxe JR, 1830, The American Dispensatory, Containing the Natural, Chemical, Pharmaceutical and Medical History of the Different Substances Employed in Medicine, Together with the Operations of Pharmacy
Crandall LA, 1931, Acquired tolerance to and cross tolerance between the nitrous and nitric acid esters and sodium nitrite in man, J Pharmacol Exp Ther, 41, 103
Dancik Y, 2010, Toxicology of the Skin: Target Organ Toxicology Series, 69
Dasta JF, 1982, Topical nitroglycerin: a new twist to an old standby, Am Pharm, 22, 29
Devane J, 1991, In vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation, Eur J Drug Metab Pharmacokinet, 3, 297
Drugs(2014).Scopolamine dosage[Online]. Available at:http://www.drugs.com/dosage/scopolamine.html(accessed 10/14/2014).
Ebbell B, 1937, The Papyrus Ebers: the Greatest Egyptian Medical Document
EbertCD PatelD HeiberW(1992).Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels. US Patent 5 152 997 Theratech Inc.
EMEA(2012).Guidelines on quality of transdermal patches.
EnscoreDJ GaleRM(1985).Matrix composition for transdermal therapeutic system. US Patent 4 559 222 Alza Corporation.
EtscornFT(1986).Transcutaneous application of nicotine. US Patent 4 597 961.
FDA(2004).FDA acts to remove ephedra‐containing dietary supplements from market.
FDA(2005).Safety warnings regarding use of fentanyl transdermal (skin) patches.
FDA(2007).FDA Public Health Advisory: important information for the safe use of fentanyl transdermal system (patch).
FDA(2009a).Public Health Advisory: risk of burns during MRI scans from transdermal drug patches with metallic backings.
FDA(2009b).Topical testosterone gel products (marketed as AndroGel 1% and Testim 1%): secondary exposure of children to topical testosterone products.
FDA(2011).Guidance for industry: residual drug in transdermal and related drug delivery systems.
FDA(2012a).Fentanyl patch can be deadly to children.
FDA(2012b).FDA Drug Safety Communication: rare cases of serious burns with the use of over‐the‐counter topical muscle and joint pain relievers.
FDA(2012c).FDA reminds the public about the potential for life‐threatening harm from accidental exposure to fentanyl transdermal systems (‘patches’).
FDA(2014).Orange Book. Annual Edition 34th edn. U. S. Food and Drug Administration: Silver Spring MD. Available at:http://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm(accessed 2/23/2015).
Fitzsimons MP, 1944, Gynaecomastia in stilboestrol worker, Br J Ind Med, 1, 235
FleischerR(1877).Untersuchgen uber das resporptions‐vermogen der menschlichen haut. Habilitationsschrift: 81.
Forbes RJ, 1955, Studies in Ancient Technology
Fox MJ, 1948, Treatment of Raynaud's diseases with nitroglycerine, Wis Med J, 47, 855
FrankT WallB PlattB LaneR(2014).Transdermal therapeutic system. US Patent Application 2014/0134230 A1 Novartis AG.
GafniY WeismanA AdinI(2008).Crystalline granisetron base and production process therefor. US Patent Application 2008/0242696 A1 Chemagis Ltd.
GaleRM BerggrenRG(1986).Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes. US Patent 4 615 699 Alza Corporation.
GaleRM GoetzV LeeES TaskovichLT YumSI(1986).Transdermal administration of fentanyl and device thereof. US Patent 4 588 580 Alza Corporation.
Gehlbach SH, 1974, Green‐tobacco sickness. An illness of tobacco harvesters, JAMA, 229, 1180, 10.1001/jama.1974.03230520022024
Govil SK, 1988, Drug Delivery Devices: Fundamentals and Applications, 385
GovilSK WeimannLJ(2006).Adhesive mixture for transdermal delivery of highly plasticizing drugs. US Patent 7 150 881 B2 Mylan Technologies Inc.
GovilSK RudnicEM SternerDG(1993).Transdermal nitroglycerin patch with penetration enhancers. US Patent 5 262 165 Schering Corporation.
Graybriel A, 1979, Prevention and treatment of space sickness in shuttle‐orbiter missions, Aviat Space Environ Med, 50, 171
Graybriel A, 1976, Prevention of experimental motion sickness by scopolamine absorbed through the skin, Aviat Space Environ Med, 47, 1096
Graybriel A, 1981, Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine, Aviat Space Environ Med, 52, 337
Groth H, 1983, Clonidine through the skin in the treatment of essential hypertension: is it practical?, J Hypertens Suppl, 1, 120
Hallmann, 2009, Proceedings of the Third Central European Conference of Young Egyptologists
Haynes RB, 1978, Practical management of low compliance with antihypertensive therapy: a guide for the busy practitioner, Clin Invest Med, 1, 175
Holling HE, 1944, Prevention of seasickness by drugs, Lancet, 146, 126
Holst J, 1983, Percutaneous estrogen therapy. Endometrical response and metabolic effects, Acta Obstet Gynecol Scand, 115, 676
Hopp MS, 2002, Developing custom adhesive systems for transdermal drug delivery products, Pharm Tech, 26, 30
HorstmannM KursaweM DzekanH(1998).Transdermal therapeutic system comprising the active substance 17‐β‐estradiol (anhydrous). US Patent 5 827 245 LTS Lohmann Therapie‐Systeme GmbH & Co.
Horton R, 1965, Testosterone production and metabolic clearance rates with volumes of distribution in normal adult men and women, Acta Endocrinol (Copenh), 48, 446
Hougham AJ, 1989, Improved skin adherence and patient acceptance in a new transdermal nitroglycerin delivery system, Clin Ther, 11, 23
Johnstone RT, 1948, Occupational Medicine and Industrial Hygiene
Kao J, 1987, Skin absorption and cutaneous first pass metabolism of topical steroids: in vitro studies with mouse skin in organ culture, J Pharmacol Exp Ther, 241, 482
Kasting GB, 1987, Pharmacology and the Skin, 138
KeithAD SnipesW(1981a).Polymeric diffusion matrix containing a vasodilatator. US Patent 4 291 015 Key Pharmaceuticals Inc.
KeithAD SnipesW(1981b).Polymeric diffusion matrix containing phenylephrine. US Patent 4 294 820 Key Pharmaceuticals Inc.
KeithAD SnipesW(1981c).Polymeric diffusion matrix containing phenylpropanolamine. US Patent 4 289 749 Key Pharmaceuticals Inc.
KeithAD SnipesW(1981d).Polymeric diffusion matrix containing ephedrine. US Patent 4 292 301 Key Pharmaceuticals Inc.
Klugo RC, 1978, Response of micropenis to topical testosterone and gonadotropin, J Urol, 119, 667, 10.1016/S0022-5347(17)57584-9
Kramer SN, 1963, The Sumerians: Their History, Culture, and Character
Kremers E, 1976, Kremers and Urdang's History of Pharmacy
KrivonosS WeismanA(2013).Crystalline rotigotine base and production process therefor. US Patent 8 344 165 B2 Chemagis Ltd.
Kydonieus AF, 1999, Biochemical Modulation of Skin Reactions: Transdermals, Topicals, Cosmetics, 1
LauterbachT SchachtDW WolffH‐M MullerW(2002).Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine. Eur Patent 1256339 A1 Schwarz Pharma AG.
Laws GC, 1898, The effects of nitroglycerin upon those who manufacture it, JAMA, 31, 793
LaWall CH, 1927, Four Thousand Years of Pharmacy: an Outline History of Pharmacy and the Allied Sciences, 10.1097/00007611-192705000-00025
LeeES NedbergeDE YumSI(1995).Transdermal administration of oxybutynin. US Patent 5 411 740 Alza Corporation.
Levin C, 2008, Marzulli and Maibach's Dermatotoxicology, 101
Lilienthal JL, 1945, The effect of hyoscine on airsickness, J Aviat Med, 16, 59
Lucas A, 1962, Ancient Egyptian Materials and Industries
Lund F, 1948, Percutaneous nitroglycerin treatment in cases of peripheral circulatory disorders, especially Raynaud's disease, Acta Med Scand, 131, 196, 10.1111/j.0954-6820.1948.tb12036.x
Maier‐Lenz H, 1980, Pharmacokinetics and relative bioavailability of a nitroglycerin ointment formulation, Arzneimittelforschung, 30, 320
Malkinson FD, 1963, Handbuch der Haut und Geschlecht Skrauberten, Normale, und Pathologische Physiologic der Haut, 90
Marathon Pharmaceuticals News(2014).Marathon pharmaceuticals launches ZiNGO® (lidocaine Hydrochloride monohydrate) powder intradermal injection system topical local [Online]. Available at:http://marathonpharma.com/marathon‐pharmaceuticals‐launches‐zingo‐lidocaine‐hydrochloride‐monohydrate‐powder‐intradermal‐injection‐systemtopical‐local‐anesthetic‐to‐manage‐venous‐access‐pain/(accessed 11/4/2014).
Mausar JT, 2011, Testing and evaluating the performance of pressure sensitive adhesives (PSAs) for TDDS patches, TransDermal, 5, 15
McAdam B, 1996, Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase, J Pharmacol Exp Ther, 277, 559
McNeil Consumer & Specialty Pharmaceuticals(2002).McNeil Consumer & Specialty Pharmaceuticals Report 2002 [Online]. Available at:http://www.fda.gov/ohrms/dockets/ac/02/briefing/3882B1_13_McNeil‐Acetaminophen.pdf(accessed 11/30/2014).
MillerKJ GovilSK BhatiaKS(2009).Fentanyl suspension‐based silicone adhesive formulations and devices for transdermal delivery of fentanyl. US Patent 7 556 823 B2 Mylan Pharmaceuticals Inc.
Moghimi HR, 2011, Drug Delivery Systems in Iranian Traditional Pharmacy
MullerW HorstmannM(1999).Estradiol‐TTS having water‐binding additives. US Patent 5 902 602 LTS Lohmann Therapie‐Systeme GmbH.
Nitto(2013).Nitto press release [Online]. Available at:http://www.nitto.com/press/2013/0628.jsp(accessed 4/6/2014).
Nyiri W, 1932, About the fate of free iodine upon application to the unbroken animal skin: an experimental study, J Pharmacol Exp Ther, 45, 85
Organization for Economic Cooperation and Development(2004).OECD guidelines for testing chemicals – test no. 428: skin absorption:in vitromethod.
OsborneJL NelsonM EnscoreDJ YumSI GaleRM(1991).Subsaturated nicotine transdermal therapeutic system. US Patent 5 004 610 Alza Corporation.
Padula C, 2007, Bioadhesive film for dermal and transdermal drug delivery, Eur J Dermatol, 17, 309
Pereira J, 1839, The Elements of Materia Medica; Comprehending the Natural History, Preparation, Properties, Composition, Effects, and Uses of Medicines
Peterson TA, 1997, Transdermal and Topical Drug Delivery Systems, 249
Pfister WR, 1997, Transdermal and Topical Drug Delivery Systems, 249
Ph Eur(2015).2.9.4. Dissolution test for transdermal patches. Ph Eur 8th edn.
Popli S, 1983, Transdermal clonidine for hypertensive patients, Clin Ther, 5, 624
Real Pharma(2014).Fat & weight loss patch [Online]. Available at:http://www.realpharma.com/generic/fat_patch.htm(accessed 3/30/2014).
Roberts MS, 2002, Dermatological and Transdermal Formulations, 97
Roberts MS, 1998, Dermal Absorption and Toxicity Assessment, 1
Rose PG, 1993, Fentanyl transdermal system overdose secondary to cutaneous hyperthermia, Anesth Analg, 77, 390, 10.1213/00000539-199308000-00029
SablotskyS QuestelJM ThompsonJA(1993).Adhesive transdermal dosage. US Patent 5 186 938 Key Pharmaceuticals Inc.
SanvordekerDR CooneyJG WesterRC(1982).Transdermal nitroglycerin pad. US Patent 4 336 243 G. F Searle & Co.
Schwenkenbecker A, 1904, Das absorptions verniogen der haut, Arch Anat Physiol, 28, 121
Sci Finder Scholar(2014).Substance identifier[Online]. Available at:https://scifinder.cas.org/(accessed 2/23/2015).
Shaw JE, 1985, Rate Control in Drug Therapy, 65
Shaw JE, 1975, Use of percutaneous absorption for systemic administration of drugs, Pharm J, 215, 32
Shaw JE, 1983, Mild Hypertension, 134
Singh H, 1979, Pharmacokinetics of norethindrone acetate in women, Am J Obstet Gynecol, 135, 409, 10.1016/0002-9378(79)90715-4
Singh J, 2002, Dermatological and transdermal formulations, 570
Smith PK, 1946, Use of hyoscine hydrobromide for the prevention or airsickness in flexible gunnery students, J Aviat Med, 17, 346
Smith PK, 1946, The effectiveness of some motion sickness remedies in preventing airsickness in air force navigation students, J Aviat Med, 17, 343
StrickerH(1983).Transdermal release system for pharmaceutical preparation. US Patent 4 409 206 Boehringer Ingelheim GmbH.
Synera(2014).Prescribing information [Online]. Available at:http://www.synera.com/(accessed 10/15/2014).
TangJ DeverichJM MillerJM BesteRD(2008).Amorphous drug transdermal systems manufacturing methods and stabilization. US Patent Application 2008/0226698 A1 Mylan Technologies Inc.
The Medicines Company(2012).News release [Online]. Available at:http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol‐newsArticle&ID=1766469&highlight=(accessed: 3/26/2014).
USP(2014a).General Chapter <3> Topical and transdermal drug products – product quality tests. First Supplement to USP 37‐NF 32.
USP(2014b).General Chapter <724> Drug release. Second Supplement to USP 37‐NF 32.
UrquhartJ KumarS ChandrasekaranSK ShawJE(1977).Bandage for transdermally administering scopolamine to prevent nausea. US Patent 4 031 894 Alza Corporation.
Wick KA, 1989, Adhesion‐to‐skin performance of a new transdermal nitroglycerin adhesive patch, Clin Ther, 11, 417
WickSM(1988).Transdermal nitroglycerin delivery system. US Patent 4 751 087 Riker Laboratories Inc.
Wilson JB, 1930, Nicotine poisoning by absorption through the skin, Br Med J, 2, 601
ZaffaroniA(1971).Bandage for administering drugs. US Patent 3 598 122 Alza Corporation.
ZaffaroniA(1973).Bandage for controlled release of vasodilatators. US Patent 3 742 951 Alza Corporation.
ZaffaroniA(1974).Bandage for the administration of drug by controlled metering through microporous materials. US Patent 3 797 494 Alza Corporation.
ZeileK HauptmannK‐H StahleH(1965).Shaving composition and method of using same. US Patent 3 190 802 Boehringen Ingelheim GmbH.
Zondek B, 1942, The excretion of halogenated phenols and their use in the treatment of urogenital infections, J Urol, 48, 747, 10.1016/S0022-5347(17)70766-5